Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
The autoimmune diagnostics company posted first-quarter 2026 revenue of $17.3 million, up 12% from the prior year, according to President and CEO John Aballi. Gross margin was 59%, and adjusted EBITDA loss narrowed to $2.2 million, a 14% improvement year over year.
